AIM - Why Is Cancer Focused Microcap Stock AIM ImmunoTech Trading Higher Today? | Benzinga
AIM ImmunoTech Inc (NYSE: AIM) announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen (rintatolimod) as a component of a Chemokine-Modulating (CKM) regimen for the treatment of early-stage triple-negative breast cancer (TNBC).
The topline results from the Phase 1 study confirm the positive findings previously presented at the ...